Pro-inflammatory effects of the aminobisphosphonate ibandronate in vitro and in vivo

Rheumatology

Volumn 38, Issue 10, 1999, Pages 984-991

  Richards, P J ^a   Amos, N ^a   Williams, A S ^a   Williams, B D ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Antigen induced arthritis; Ibandronate; Interferon ; Mononuclear cells; Tumour necrosis factor

Indexed keywords

CYTOKINE; GAMMA INTERFERON; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; IBANDRONIC ACID; LIPOPOLYSACCHARIDE; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; CELL INTERACTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN CELL; INTRAARTICULAR DRUG ADMINISTRATION; MALE; MONOCYTE; MONONUCLEAR CELL; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RAT; TIME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS; ARTHRITIS; CHRONIC DISEASE; DIPHOSPHONATES; DNA PRIMERS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; INJECTIONS, INTRA-ARTICULAR; INTERFERON TYPE II; KNEE JOINT; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; MALE; NEUTRALIZATION TESTS; POLYMERASE CHAIN REACTION; RATS; RATS, INBRED LEW; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032744894     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/38.10.984     Document Type: Article

References (59)

1. Shinoda H, Adamek G, Felix R, Fleisch H, Schenk R, Hagan P. Structure-activity relationships of various bisphosphonates. Calcif Tissue Int 1983;35:87-99.
2. Fleisch H. Bisphosphonates in bone disease - From the laboratory to the patient. New York: The Parthenon Group, 1995.
3. Naito M, Nagai H, Kawano S et al. Liposome-encapsulated dichloromethylene diphosphonate induces macrophage apoptosis in vivo and in vitro. J Leukoc Biol 1996;60:337-44.
4. Van Rooijen N, Sanders A, van den Berg TK. Apoptosis of macrophages induced by liposome-mediated intracellular delivery of clodronate and propamidine. J Immunol Methods 1996;193:93-9.
5. Schmidt-Weber CB, Rittig M, Buchner E et al. Apoptotic cell death in activated monocytes following incorporation of clodronate-liposomes. J Leukoc Biol 1996;60:230-44.
6. Frith JC, Monkkonen J, Blackburn GM, Russell RGG, Rogers MJ. Clodronate and liposome-encapsulated clodronate are metabolised to a toxic ATP analog, adenosine 5′-(β, γ-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 1997;12:1358-67.
7. Selander KS, Monkkonen J, Karhukorpi E-K, Harkonen PL, Hannuniemi R, Vaananen HK. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol 1996;50:1127-38.
8. Monkkonen J, Pennanen N, Lapinjoki S, Urtti A. Clodronate (dichloromethylene bisphosphonate) inhibits LPS-stimulated IL-6 and TNF production by RAW 264 cells. Life Sci 1994;54:PL229-34.
9. Pennanen N, Lapinjoki S, Urtti A, Monkkonen J. Effect of liposomal and free bisphosphonates on the IL-1, IL-6 and TNF secretion from RAW 264 cells in vitro. Pharm Res 1995;12:916-22.
10. Camilleri JP, Williams AS, Amos N, Douglas-Jones AG, Williams BD. Liposomal clodronate depletes synovial macrophages, suppresses inflammation and prevents radiological progression in adjuvant arthritis. Arthritis Rheum 1995;38(suppl. 9):1319.
11. Kinne RW, Schmidt CB, Buchner E, Hoppe R, Nurnberg E, Emmrich F. Treatment of rat arthritides with clodronate-containing liposomes. Scand J Rheumatol 1995;24(suppl. 101):91-7.
12. Van Lent PLEM, van den Bersselaar LAM, Holthuysen AEM, van Rooijen N. Phagocytic synovial lining cells in experimentally induced chronic arthritis: down-regulation of synovitis by C12-MDP-liposomes. Rheumatol Int 1994;13:221-8.
13. Kinne RW, Schmidt-Weber CB, Hoppe R et al. Long-term amelioration of rat adjuvant arthritis following systemic elimination of macrophages by clodronate-containing liposomes. Arthritis Rheum 1995;38:1777-90.
14. Van Lent PLEM, van den Bersselaar L, van den Hoek AEM et al. Reversible depletion of synovial lining cells after intra-articular treatment with liposome-encapsulated dichloromethylene diphosphonate. Rheumatol Int 1993;13:21-30.
15. Allison AC, Feruga J, Prydz H, Schorlemmer HU. The role of macrophage activation in chronic inflammation. Agents Actions 1978;8:27-35.
16. Firestein GS, Zvaifler NJ. Peripheral blood and synovial fluid monocyte activation in inflammatory arthritis. II. Low levels of synovial fluid and synovial tissue interferon suggest that gamma-interferon is not the primary macrophage activating factor. Arthritis Rheum 1987;30:864-71.
17. Ishikawa H, Ziff M. Electron microscopic observations of immunoreactive cells in the rheumatoid synovial membrane. Arthritis Rheum 1976;19:1-14.
18. Miossec P, Dinarello CA, Ziff M. Interleukin-1 lympho-cyte chemotactic activity in rheumatoid arthritis synovial fluid. Arthritis Rheum 1986;29:461-70.
19. Noun AM, Panayi GS, Goodman SM. Cytokines and the chronic inflammation of rheumatic disease. I. The presence of interleukin-1 in synovial fluids. Clin Exp Immunol 1984;55:295-302.
20. Guerne PA, Zuraw BL, Vaughan JH, Carson DA, Lotz M. Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis. J Clin Invest 1989;83:585-92.
21. Saxne T, Palladino MA Jr, Heinegard D, Talal N, Wollheim FA. Detection of tumour necrosis factor alpha but not tumour necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988;31:1041-5.
22. Tetta C, Camussi G, Modena V, Di Vittorio C, Baglioni C. Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Ann Rheum Dis 1990;49:665-7.
23. Firestein GS, Xu WD, Townsend K et al. Cytokines in chronic inflammatory arthritis. I. Failure to detect T cell lymphokines (interleukin 2 and interleukin 3) and presence of macrophage colony-stimulating factor (CSF-1) and a novel mast cell growth factor in rheumatoid synovitis. J Exp Med 1988;168:1573-86.
24. Van de Loo FAJ, Joosten LAB, van Lent PLEM, Arntz OJ, van den Berg WB. Role of interleukin-1, tumour necrosis factor α, and interleukin-6 in cartilage proteoglycan metabolism and destruction: effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum 1995;38:164-72.
25. Joosten LAB, Helsen MMA, van de Loo FAJ, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-YNFα, anti-IL-1α/β, and IL-1Ra. Arthritis Rheum 1996;39:797-809.
26. Elliott MJ, Maini RN, Feldmann M et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
27. Elliott MJ, Maini RN, Feldmann M et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125-7.
28. Rankin KC, Choy KH, Kassimos D et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995;334-42.
29. Muhlbauer RC, Bauss F, Schenk R et al. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 1991;6:1003-11.
30. Sauty A, Percherstorfer M, Zimmer-Roth I et al. IL-6 and TNF alpha levels after bisphosphonate treatment in vitro and in patients with malignancy. Bone 1996;18:133-9.
31. Wuster C, Schoter KH, Thiebaud D et al. Methylpentylaminopropylidene-bisphosphonate (BM 21.0955): a new potent and safe bisphosphonate for the treatment of cancer-associated hypercalcemia. Bone Miner 1993;22:77-85.
32. Griffiths RJ. Characterisation and pharmacological sensitivity of antigen arthritis induced by methylated bovine serum albumin in the rat. Agents Actions 1992;35:88-95.
33. Williams AS, Punn YL, Amos N, Cooper AM, Williams BD. The effect of liposomally conjugated methotrexate upon mediator release from human peripheral blood monocytes. Br J Rheumatol 1995;34:241-5.
34. Van de Loosd AA, Nennie E, Ossenkoppele GJ, Beelen RH, Langenhuijsen MM. Cell mediated cytotoxicity against U937 cells by human monocytes and macrophages in a modified colorimetric MTT assay. A methodological study. J Immunol Methods 1991;141:15-22.
35. Tokunaga K, Nakamura Y, Sakata K et al. Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in human lung cancers. Cancer Res 1987;47:5616-9.
36. Shirai T, Shimizu NS, Horiguchi S, Ito H. Cloning and expression in Escherichia coli of the gene for rat tumour necrosis factor. Agric Biol Chem 1989;53:1733-6.
37. Nishi T, Fujita T, Nishi-Takaoka C et al. Cloning and expression of a novel variant of human interferon-gamma cDNA. J Biochem 1985;97:153-9.
38. Francis MD, Flora L, King WR. The effects of disodium ethane-1-hydroxy-1, 1-diphosphonate on adjuvant induced arthritis in rats. Calcif Tissue Res 1972;9:109-21.
39. Flora L. Comparative antiinflammatory and bone protective effects of two diphosphonates in adjuvant arthritis. Arthritis Rheum 1979;22:340-6.
40. Glatt M, Bray MA, Bisping M, Blattler A. Effects of diphosphonate (APD, EHDP) on inflammation and bone turnover in adjuvant arthritis. Experimentia 1983;39:681.
41. Dunn CJ, Galinet LA, Wu H et al. Demonstration of novel anti-arthritic and anti-inflammatory effects of diphosphonates. J Pharmacol Exp Ther 1993;266:1691-8.
42. Osterman T, Kippo K, Lauren L, Hannuniemi R, Sellman R. Effect of clodronate on established collagen-induced arthritis in rats. Inflamm Res 1995;44:258-63.
43. Bijvoet OLM, Frijlink WB, Jie K et al. APD in Paget's disease of bone. Role of the mononuclear phagocyte system? Arthritis Rheum 1980;23:1193-204.
44. Eggelmeijer F, Papapoulos SE, van Paassen HC, Dijkmans BAC, Breedveld FC. Clinical and biochemical response to a single infusion of pamidronate in patients with active rheumatoid arthritis: a double blind placebo controlled study. J Rheumatol 1994;21:2016-20.
45. England AJ, Reid DM, Capell H, Ralston SH. Effects of oral clodronate on disease activity and bone mineral density in rheumatoid arthritis. Br J Rheumatol 1996;35(suppl. 2):21.
46. Hayes MP, Freeman SL, Donnelly RP. IFN-gamma priming of monocytes enhances LPS-induced TNF production by augmenting both transcription and MRNA stability. Cytokine 1995;7:427-35.
47. Jayaram Y, Buckle AM, Hogg N. The Fc receptor, FcRI, and other activation molecules on human mononuclear phagocytes after treatment with interferon-gamma. Clin Exp Immunol 1989;75:414-20.
48. Guyre PM, Morganelli PM, Miller R. Recombinant immune interferon increases immunoglobulin G Fc receptors on cultured human mononuclear phagocytes. J Clin Invest 1983;72:393-7.
49. Perussia B, Dayton ET, Lazarus R, Fanning V, Trinchieri G. Immune interferon induces receptor for monomeric IgG1 on human monocytic and myeloid cells. J Exp Med 1983;158:1092-113.
50. Virelizier J-L, Perez N, Arenzana-Seisdedos F, Devos R. Pure interferon gamma enhances class II HLA antigens on human monocyte cell lines. Eur J Immunol 1984;14:106-8.
51. Gonwa TA, Frost JP, Karr RW. All human monocytes have the capability of expressing HLA-DQ and HLA-DP molecules upon stimulation with interferon-γ. J Immunol 1986;137:519-24.
52. Kasahara T, Djeu JY, Dougherty SF, Oppenheim JJ. Capacity of human large granular lymphocytes (LGL) to produce multiple lymphokines: interleukin 2, interferon and colony stimulating factor. J Immunol 1983;131:2379-86.
53. Kasahara T, Hooks JJ, Dougherty SF, Oppenheim JJ. Interleukin 2-mediated immune Interferon (IFN-gamma) production by human T cells and T cell subsets. J Immunol 1983;130:1784-9.
54. Ortaldo JR, Mason AT, Gerard JP et al. Effects of natural and recombinant IL-2 on regulation of IFN-gamma production and natural killer activity: Lack of involvement of the Tac antigen for these immunoregulatory effects. J Immunol 1984;133:779-83.
55. Trichieri G, Perussia B. Immune interferon: a pleiotropic lymphokine with multiple effects. Immunol Today 1985;6:131-6.
56. Young HA, Ortaldo JR. One-single requirement for interferon-gamma production by human large granular lymphocytes. J Immunol 1987;139:724-7.
57. Monkkonen J, Simila J, Rogers MJ. Effect of tiludronate and ibandronate on the secretion of proinflammatory cytokines and nitric oxide from macrophages in vitro. Life Sci 1998;62:PL95-102.
58. Nakamura M, Ando T, Abe M, Kumagai K, Endo Y. Contrast between effects of aminobisphosphonates and non-aminobisphosphonates on collagen-induced arthritis in mice. Br J Pharmacol 1996;119:205-12.
59. Endo Y, Nakamura M, Kikuchi T et al. Aminoalkylbisphosphonates, potent inhibitors of bone resorption, induce a prolonged stimulation of histamine synthesis and increase macrophages, granulocytes, and osteoclasts in vivo. Calcif Tissue Int 1993;52:248-54.